Posted by AGORACOM-JC
at 9:36 AM on Friday, January 22nd, 2021
Announced today that the CEO of the Company, Cameron Chell, will be featured on Yahoo Finance.
Segment on Yahoo Finance will focus on Draganfly’s recent announcements in relation to Draganfly’s robust vaccine delivery payload for drone delivery of the COVID-19 vaccine.
Los Angeles, CA, Jan. 22, 2021 —Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“ Draganfly ” or the “ Company ”), an award-winning, industry-leading manufacturer and systems developer, announced today that the CEO of the Company, Cameron Chell, will be featured on Yahoo Finance.
The segment on Yahoo Finance will focus on Draganfly’s recent announcements in relation to Draganfly’s robust vaccine delivery payload for drone delivery of the COVID-19 vaccine.
“We are honored to join Yahoo Finance and discuss Draganfly’s vaccine drone delivery payload system,” said Cameron Chell, CEO Draganfly. “We are eager to develop this payload and service as we can leverage our extensive patent portfolio as well as secure auto-pilot and flight management system to help with the distribution of the vaccine for COVID-19 and beyond.”
Cameron Chell’s segment on Yahoo Finance will air at 1040AM ET on Friday, January 22.
Posted by AGORACOM-JC
at 8:47 AM on Friday, January 22nd, 2021
PyroGenesis (PYR:TSX) recently uplisted to the TSX from the TSX Venture and immediately announced plans to apply for a NASDAQ listing. Then, shareholders of PYR discovered the Company’s stock has now been included by the ARK 3D Printing ETF $PRNT …. so it looks like PYR has started off 2021 right where it left off and we sat down with CEO Peter Pascali to talk about some of the bigger topics on the minds of shareholders.
As always, Peter doesn’t disappoint. Watch this great interview.
Posted by AGORACOM-JC
at 7:57 AM on Friday, January 22nd, 2021
Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.
Herzliya, Israel and Calgary, Alberta–(January 22, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.
This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.
The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.
Posted by AGORACOM-JC
at 7:51 AM on Friday, January 22nd, 2021
Announced that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. and the shareholders of Concierge effective January 19, 2021 to acquire 100% of Concierge’s issued and outstanding securities
Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.
Toronto, Ontario–(January 22, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. (“Concierge“) and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“) to acquire 100% of Concierge’s issued and outstanding securities (the “Transaction“). Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.
“Health care is on the verge of a revolution, one that will be driven by A.I. technologies. Medical services are already strained by the growing demand for healthcare worldwide. By leveraging A.I. technologies, medical we will be able to provide services more quickly and accurately,” said Marshall Gunter, CEO of Datametrex.
Posted by AGORACOM-JC
at 7:47 AM on Friday, January 22nd, 2021
Company has been selected by bdG Sports to provide its complete venue management platform to the Paiute Las Vegas Championship, a Korn Ferry Tour event, which will be played April 12-18, 2021 at the Las Vegas Paiute Golf Resort.
Korn Ferry Tour is the developmental tour for the U.S.-based PGA Tour and features professional golfers who have either not yet reached the PGA Tour, or who have done so but then failed to win enough FedEx Cup points to stay at that level
VANCOUVER, British Columbia, Jan. 22, 2021 — Loop Insights Inc. (MTRX:TSXV OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the Company has been selected by bdG Sports to provide its complete venue management platform to the Paiute Las Vegas Championship, a Korn Ferry Tour event, which will be played April 12-18, 2021 at the Las Vegas Paiute Golf Resort.
KORN FERRY FEATURES OVER 20 TOURNAMENTS IN 2021 AS DEVELOPMENT TOUR FOR PGA TOUR
The Korn Ferry Tour is the developmental tour for the U.S.-based PGA Tour and features professional golfers who have either not yet reached the PGA Tour, or who have done so but then failed to win enough FedEx Cup points to stay at that level. Since the 2013 season, the Korn Ferry Tour has been the primary pathway for those seeking to earn their PGA Tour card.
The tournament will have a full field of 156 players who will compete for a $600,000 purse. More importantly, participants will be competing in a season-long points race with the Top 25 finishers of the regular season earning PGA TOUR cards for the 2021-22 season. Local members of the Tour include Harry Hall, David Lipsky, Taylor Montgomery, and John Oda.
The implementation of Loop’s venue management platform at the Paiute Las Vegas Championship is another significant vote of confidence from the professional sports world following the successful deployment of our venue management platform at multiple live events.
Posted by AGORACOM-JC
at 6:53 PM on Thursday, January 21st, 2021
Today’s press release from HPQ might have been a little technical for newcomers but the words from CEO Bernard Tourillon explain exactly how important it was:
“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications ….. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Moreover, Tourillon couldn’t help but display his feelings and proclaimed this was going to be a fun year for HPQ.
Posted by AGORACOM-JC
at 12:46 PM on Thursday, January 21st, 2021
Announced that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents 17,810,000 Special Warrants of the Company on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 for total gross proceeds of up to $6,500,650
Each Special Warrant shall be automatically exercisable into units of the Company, as described below. Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant
VANCOUVER, British Columbia, Jan. 21, 2021 — Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“ Hollister ” or the “ Company ”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents (together with Eight Capital, the “ Agents ”), 17,810,000 Special Warrants of the Company (the “ Special Warrants ”), on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 (the “ Issue Price ”) for total gross proceeds of up to $6,500,650 (the “ Offering ”).
Each Special Warrant shall be automatically exercisable into units of the Company (the “ Units ”), as described below. Each Unit shall consist of one common share of the Company (a “ Share ”) and one-half of one common share purchase warrant (each full warrant, a “ Warrant ”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $0.50 per Share for a period of 46 months following the Closing Date.
Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “ Automatic Exercise Date ”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “ Securities Commissions ”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “ Qualifying Prospectus ”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “ Qualifying Supplement ”), and (ii) the date that is four months and one day after the Closing of the Offering.
Posted by AGORACOM-JC
at 9:38 AM on Thursday, January 21st, 2021
Q3 2020 Financial Highlights:
Revenue increased by more than 100% in Q3 2020, in comparison to Q3 2019.
A combined $3.12 Million raised through private placement subscriptions with strategic investors.
January 21, 2021 – Toronto – Binovi Technologies Corp. (Binovi) (TSXV:VISN ) I ( OTC:BNVIF ) | ( GR:2EYA ) a leader in neuro-vision performance technology, reports results for the Company’s fiscal third quarter, ended November 30, 2020. The Company’s net sales results continue to be affected by the global health crisis. Increased demand for products across multiple categories led to an increase in top-line and gross margin results.
“Strategically positioned within telehealth, we believe the coming quarters will be pivotal in establishing our reputation and status as a competitor within this rapidly growing marketplace. While we are seeing strong growth across the business, it is important to recognize that we are making big investments in our people and infrastructure that are essential to support the significant growth that lies ahead. This includes big investments in our telehealth SaaS, our provider network, and personnel are critical as we scale the business,” stated Executive Chairman, Terry Booth.
Q3 2020 Financial Highlights:
Revenue increased by more than 100% in Q3 2020, in comparison to Q3 2019.
A combined $3.12 Million raised through private placement subscriptions with strategic investors.
Operational Highlights:
Since the launch of Binovi, more than 800 organizations have been registered and have used the platform for vision therapy and/or sports vision performance. These organizations have created nearly 31,000 users, together completing more than 400,000 active sessions centered around the Binovi Library list of activities, custom activities created by our member organizations.
Advanced the development of the company’s web-based telehealth SaaS, Binovi Connect. The beta launch of the platform is planned for Q1 2021.
Product marketing continues to grow brand awareness and promote sales, with an increase of 300% in website traffic, with improvements in direct media marketing and general top-of-mind awareness.
